Seeking Alpha

Bay Area Biotech  

View Bay Area Biotech's Comments BY TICKER:
  • DiaDexus: A Hearty Choice [View article]
    Thank you for providing information on the Galectin-3 diagnostic test being commercialized by BG Medicine (BGMD). Since it applies to patients who have already been diagnosed with chronic heart failure, it applies to a niche market and would come one or two steps after the PLAC test in the increasingly useful arsenal of cardiovascular diagnostic tests available to physicians. We do not see it as a direct or indirect competitor to the PLAC test.
    Sep 10, 2013. 01:46 AM | Likes Like |Link to Comment
More on DDXS by Bay Area Biotech
COMMENTS STATS
25 Comments
9 Likes